ReviewThe Journal of physiology2025
Chemoreflex function in pulmonary diseases - A review.
Review in The Journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevention of Sleep Apnoea After General Anaesthesia Using a Thermoplastic Mandibular Advancement Device: A Randomised, Controlled, Single-Blind Trial.Journal of clinical medicine · 2026Article
- Editorial: Chemical senses in health and disease.Frontiers in neural circuits · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The chemoreflex is a vital protective reflex that is crucial in restoring normal blood gas and pH levels. The carotid bodies are peripheral chemoreceptors activated by hypoxia (primarily), hypercapnia, acidaemia, temperature, lactate and potassium fluctuations. They are crucial for maintaining physiological conditions based on underlying causes and blood gas abnormalities. Central chemoreceptors in the brain stem are responsive to hypercapnia and contribute to blood gas regulation. Chemoreceptors regained attention during the SARS-CoV-2 (COVID-19) pandemic, potentially contributing to disease severity. In conditions like chronic intermittent hypoxia, chemoreflex sensitization may lead to respiratory disorders, impacting quality of life. There has been substantial research/evidence linking chemoreflex dysfunction to cardiovascular illnesses such as heart failure and hypertension. However, little emphasis has been placed on the role of the chemoreflex in mediating cardiopulmonary dysfunction during and after pulmonary disorders such as acute lung injury. The current review summarizes recent advances in the study of chemoreflex malfunction and the underlying mechanisms in acute and chronic lung diseases such as COVID-19 infection, chronic obstructive pulmonary disease, asthma, obstructive sleep apnoea and acute lung injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.